The Prostate Health Education Network: Prostate Health Education and Awareness

Clinical Trials

Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients Number: NCT00579514 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients Number: NCT00579514 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients Number: NCT00579514 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer Number: NCT00588185 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
A Study of Patients Receiving High-Dose Rate Brachytherapy Number: NCT00924027 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s):	Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy Number: NCT00969111 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Trial of Modifications to Radical Prostatectomy Number: NCT01407263 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Memorial Sloan Kettering Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s):	MRI-Mapped Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial Number: NCT01411345 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2\|Phase 3 Sponsor(s): University of Miami Sponsor Trial Information Trial Location(s) and Contact(s):
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer Number: NCT01492972 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Proton Collaborative Group Sponsor Trial Information Trial Location(s) and Contact(s):	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer Number: NCT01581749 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 4 Sponsor(s): Albert DeNittis\|Main Line Health Sponsor Trial Information Trial Location(s) and Contact(s):
Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer Number: NCT01581749 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 4 Sponsor(s): Albert DeNittis\|Main Line Health Sponsor Trial Information Trial Location(s) and Contact(s):	MRI for Assessing Prostate Cancer Response Number: NCT01607008 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
MR-Guided Cryoablation of Prostate Bed Recurrences Number: NCT01727284 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	Radiation Hypofractionation Via Extended Versus Accelerated Therapy (HEAT) For Prostate Cancer Number: NCT01794403 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Controlled Low Calorie Diet in Reducing Side Effects and Increasing Response to Chemotherapy in Patients With Breast or Prostate Cancer Number: NCT01802346 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	Controlled Low Calorie Diet in Reducing Side Effects and Increasing Response to Chemotherapy in Patients With Breast or Prostate Cancer Number: NCT01802346 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer Number: NCT01913106 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): The Methodist Hospital Research Institute Sponsor Trial Information Trial Location(s) and Contact(s):	CyberKnife® as Monotherapy or Boost SBRT for Intermediate or High Risk Localized Prostate Cancer Number: NCT01985828 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
CyberKnife® as Monotherapy or Boost SBRT for Intermediate or High Risk Localized Prostate Cancer Number: NCT01985828 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	Evaluation of CyberKnife Stereotactic Radiotherapy in Prostate Cancer Number: NCT02016248 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Hypofractionated Image Guided Proton Therapy for Low andIntermediate Risk Prostate Cancer Number: NCT02040610 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	Hypofractionated Image Guided Proton Therapy for Low andIntermediate Risk Prostate Cancer Number: NCT02040610 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy Number: NCT02064673 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): yair lotan\|University of Texas Southwestern Medical Center Sponsor Trial Information Trial Location(s) and Contact(s):	A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts Number: NCT02266745 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Promontory Therapeutics Inc. Sponsor Trial Information Trial Location(s) and Contact(s):
A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts Number: NCT02266745 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Promontory Therapeutics Inc. Sponsor Trial Information Trial Location(s) and Contact(s):	A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts Number: NCT02266745 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Promontory Therapeutics Inc. Sponsor Trial Information Trial Location(s) and Contact(s):
A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts Number: NCT02266745 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Promontory Therapeutics Inc. Sponsor Trial Information Trial Location(s) and Contact(s):	A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts Number: NCT02266745 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Promontory Therapeutics Inc. Sponsor Trial Information Trial Location(s) and Contact(s):
A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts Number: NCT02266745 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Promontory Therapeutics Inc. Sponsor Trial Information Trial Location(s) and Contact(s):	A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts Number: NCT02266745 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Promontory Therapeutics Inc. Sponsor Trial Information Trial Location(s) and Contact(s):
68Ga-PSMA PET-CT Scan for Diagnosis and Management of Prostate Cancer Number: NCT02282137 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Ebrahim Delpassand\|Radiomedix, Inc.\|Excel Diagnostics and Nuclear Oncology Center\|Radio Isotope Therapy of America Sponsor Trial Information Trial Location(s) and Contact(s):	Randomized MRI-Guided Prostate Boosts Via Initial Lattice Stereotactic vs Daily Moderately Hypofractionated Radiotherapy Number: NCT02307058 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Stereotactic Body Radiotherapy for Stage I-III Prostate Cancer Number: NCT02334579 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	Stereotactic Body Radiotherapy for Stage I-III Prostate Cancer Number: NCT02334579 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Evaluation of PSMA-based PET as an Imaging Biomarker in Prostate Cancer Number: NCT02420977 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer Number: NCT02452008 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|Eli Lilly and Company Sponsor Trial Information Trial Location(s) and Contact(s):
Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer Number: NCT02452008 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|Eli Lilly and Company Sponsor Trial Information Trial Location(s) and Contact(s):	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Number: NCT02465060 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can Number: NCT02484404 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s):	Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can Number: NCT02484404 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s):
Enzalutamide With and Without Ribociclib for Metastatic, Castrate-Resistant, Chemotherapy-Naive Prostate Cancer That Retains RB Expression Number: NCT02555189 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Sidney Kimmel Cancer Center at Thomas Jefferson University\|Novartis\|Prostate Cancer Clinical Trials Consortium\|Thomas Jefferson University Sponsor Trial Information Trial Location(s) and Contact(s):	Enzalutamide With and Without Ribociclib for Metastatic, Castrate-Resistant, Chemotherapy-Naive Prostate Cancer That Retains RB Expression Number: NCT02555189 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Sidney Kimmel Cancer Center at Thomas Jefferson University\|Novartis\|Prostate Cancer Clinical Trials Consortium\|Thomas Jefferson University Sponsor Trial Information Trial Location(s) and Contact(s):
Focal Laser Ablation of Low to Intermediate Prostate Cancer Tumors Number: NCT02600156 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	Focal Laser Ablation of Low to Intermediate Prostate Cancer Tumors Number: NCT02600156 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer Number: NCT02635672 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Vincerx Pharma, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):	Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer Number: NCT02635672 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Vincerx Pharma, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):
Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer Number: NCT02643667 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Washington University School of Medicine\|Pharmacyclics LLC. Sponsor Trial Information Trial Location(s) and Contact(s):	Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications Number: NCT02649790 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Karyopharm Therapeutics Inc Sponsor Trial Information Trial Location(s) and Contact(s):
Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors Number: NCT02717156 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Southern California\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors Number: NCT02717156 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Southern California\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors Number: NCT02744287 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Bellicum Pharmaceuticals Sponsor Trial Information Trial Location(s) and Contact(s):	Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors Number: NCT02744287 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Bellicum Pharmaceuticals Sponsor Trial Information Trial Location(s) and Contact(s):
Pivotal Study of MRI-guided Transurethral Ultrasound Ablation in Patients With Localized Prostate Cancer Number: NCT02766543 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer Number: NCT02769962 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s):
Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer Number: NCT02769962 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s):	Preliminary Evaluation of Uptake in Bone Metastases and Biodistribution of [68Ga]P15-041 Number: NCT02826382 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): Five Eleven Pharma, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):
Preliminary Evaluation of Uptake in Bone Metastases and Biodistribution of [68Ga]P15-041 Number: NCT02826382 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): Five Eleven Pharma, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):	Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) Number: NCT02861573 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Merck Sharp & Dohme LLC Sponsor Trial Information Trial Location(s) and Contact(s):
PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer Number: NCT02933255 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s):	PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer Number: NCT02933255 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s):
Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer Number: NCT02935205 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Mamta Parikh\|National Cancer Institute (NCI)\|University of California, Davis Sponsor Trial Information Trial Location(s) and Contact(s):	Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer Number: NCT02935205 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Mamta Parikh\|National Cancer Institute (NCI)\|University of California, Davis Sponsor Trial Information Trial Location(s) and Contact(s):
Study of Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients Receiving Androgen Deprivation Therapy Number: NCT02946996 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Medical University of South Carolina Sponsor Trial Information Trial Location(s) and Contact(s):	Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery Number: NCT02949284 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Rutgers, The State University of New Jersey\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study Number: NCT02960022 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Astellas Pharma Global Development, Inc.\|Pfizer\|Astellas Pharma Inc Sponsor Trial Information Trial Location(s) and Contact(s):	Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects Number: NCT03012321 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Northwestern University\|AstraZeneca\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects Number: NCT03012321 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Northwestern University\|AstraZeneca\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer Number: NCT03016741 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 4 Sponsor(s): Northwestern University Sponsor Trial Information Trial Location(s) and Contact(s):
Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer Number: NCT03016741 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 4 Sponsor(s): Northwestern University Sponsor Trial Information Trial Location(s) and Contact(s):	Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis Number: NCT03047135 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|AstraZeneca Sponsor Trial Information Trial Location(s) and Contact(s):
Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis Number: NCT03047135 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|AstraZeneca Sponsor Trial Information Trial Location(s) and Contact(s):	Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System Number: NCT03067051 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Preliminary Evaluation of Uptake of [68Ga]P16-093 in Metastatic Prostate and Renal Cancer Number: NCT03073395 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Five Eleven Pharma, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):	Preliminary Evaluation of Uptake of [68Ga]P16-093 in Metastatic Prostate and Renal Cancer Number: NCT03073395 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Five Eleven Pharma, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):
Magnetic Resonance Whole Body Diffusion-Weighted Imaging in Finding Bone or Lymph Node Metastasis in Participants With High-Risk Prostate Cancer Number: NCT03085043 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	A Study of Grape Seed Extract in Asymptomatic Non-Metastatic Prostate Cancer Patients With Rising PSA Number: NCT03087903 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
CART-PSMA-TGFβRDN Cells for Castrate-Resistant Prostate Cancer Number: NCT03089203 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): University of Pennsylvania Sponsor Trial Information Trial Location(s) and Contact(s):	A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide� Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors Number: NCT03129139 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Minneamrita Therapeutics LLC\|Translational Drug Development Sponsor Trial Information Trial Location(s) and Contact(s):
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide� Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors Number: NCT03129139 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Minneamrita Therapeutics LLC\|Translational Drug Development Sponsor Trial Information Trial Location(s) and Contact(s):	PSMA-based 18F-DCFPyL PET/CT and PET/MRI Pilot Studies in Prostate Cancer Number: NCT03232164 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): University of Wisconsin, Madison Sponsor Trial Information Trial Location(s) and Contact(s):
PSMA-based 18F-DCFPyL PET/CT and PET/MRI Pilot Studies in Prostate Cancer Number: NCT03232164 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): University of Wisconsin, Madison Sponsor Trial Information Trial Location(s) and Contact(s):	Prostate SBRT for Locally Recurrent Prostate Cancer After Prior Radiotherapy Number: NCT03253744 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s):
Cisplatin in Castration Resistant Prostate Cancer Number: NCT03275857 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): University of Rochester\|Roswell Park Cancer Institute Sponsor Trial Information Trial Location(s) and Contact(s):	Focal Salvage HDR Brachytherapy for Locally Recurrent Prostate Cancer in Patients Treated With Prior Radiotherapy Number: NCT03312972 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Loyola University Sponsor Trial Information Trial Location(s) and Contact(s):
Combination Immunotherapy in Biochemically Recurrent Prostate Cancer Number: NCT03315871 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s):	Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis Number: NCT03317392 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis Number: NCT03317392 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors Number: NCT03333616 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Dana-Farber Cancer Institute\|Bristol-Myers Squibb Sponsor Trial Information Trial Location(s) and Contact(s):
Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer Number: NCT03361735 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): City of Hope Medical Center Sponsor Trial Information Trial Location(s) and Contact(s):	Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer Number: NCT03361735 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): City of Hope Medical Center Sponsor Trial Information Trial Location(s) and Contact(s):
Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy Number: NCT03388619 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s):	Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy Number: NCT03388619 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s):
PET/MRI for the Staging of Newly Diagnosed Prostate Cancer Number: NCT03392181 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): Northwestern University\|Progenics Pharmaceuticals, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):	PET/MRI for the Staging of Newly Diagnosed Prostate Cancer Number: NCT03392181 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): Northwestern University\|Progenics Pharmaceuticals, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):
PET/MRI for the Staging of Newly Diagnosed Prostate Cancer Number: NCT03392181 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): Northwestern University\|Progenics Pharmaceuticals, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):	Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations Number: NCT03413995 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|Clovis Oncology, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):
Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Number: NCT03419234 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): ECOG-ACRIN Cancer Research Group\|National Cancer Institute (NCI)\|Eastern Cooperative Oncology Group Sponsor Trial Information Trial Location(s) and Contact(s):	The "PC-LIGHT" Study Number: NCT03419585 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Safety and Efficacy of 21 Gy, 23 Gy and 25 Gy for High Dose Rate (HDR) Prostate Brachytherapy Number: NCT03424850 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Washington University School of Medicine Sponsor Trial Information Trial Location(s) and Contact(s):	Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma Number: NCT03436654 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Memorial Sloan Kettering Cancer Center\|Dana-Farber Cancer Institute Sponsor Trial Information Trial Location(s) and Contact(s):
The Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration In Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females Number: NCT03436745 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s):	Study to Evaluate CORT125281 in Combination With Enzalutamide in Patients With mCRPC Number: NCT03437941 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Corcept Therapeutics Sponsor Trial Information Trial Location(s) and Contact(s):
Study to Evaluate CORT125281 in Combination With Enzalutamide in Patients With mCRPC Number: NCT03437941 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Corcept Therapeutics Sponsor Trial Information Trial Location(s) and Contact(s):	Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer Number: NCT03456843 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Yale University\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer Number: NCT03456843 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Yale University\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	RAD 1801: Pilot Study of Intra-Urethral Radiotransponder Beacon Guided Focal Prostate Stereotactic Body Radiotherapy Number: NCT03458234 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma Number: NCT03460977 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Pfizer Sponsor Trial Information Trial Location(s) and Contact(s):	PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma Number: NCT03460977 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Pfizer Sponsor Trial Information Trial Location(s) and Contact(s):
PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma Number: NCT03460977 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Pfizer Sponsor Trial Information Trial Location(s) and Contact(s):	PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma Number: NCT03460977 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Pfizer Sponsor Trial Information Trial Location(s) and Contact(s):
Ultra-hypofractionated Radiation in Prostate Cancer Number: NCT03486821 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	Ultra-hypofractionated Radiation in Prostate Cancer Number: NCT03486821 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1) Number: NCT03493945 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s):	Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1) Number: NCT03493945 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s):
PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores Number: NCT03495427 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2\|Phase 3 Sponsor(s): H. Lee Moffitt Cancer Center and Research Institute\|Progenics Pharmaceuticals, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):	Effects of Muscadine Grape Extract in Men With Prostate Cancer on Androgen Deprivation Therapy Number: NCT03496805 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Wake Forest University Health Sciences Sponsor Trial Information Trial Location(s) and Contact(s):
Apalutamide With or Without Stereotactic Body Radiation Therapy in Treating Participants With Castration-Resistant Prostate Cancer (PILLAR) Number: NCT03503344 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of California, San Francisco\|Janssen Pharmaceuticals Sponsor Trial Information Trial Location(s) and Contact(s):	Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen Suppression Number: NCT03507608 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Sponsor Trial Information Trial Location(s) and Contact(s):
Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen Suppression Number: NCT03507608 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Sponsor Trial Information Trial Location(s) and Contact(s):	Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen Suppression Number: NCT03507608 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Sponsor Trial Information Trial Location(s) and Contact(s):
Prostate Oncologic Therapy While Ensuring Neurovascular Conservation (POTEN-C) Number: NCT03525262 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Texas Southwestern Medical Center\|Boston Scientific Corporation Sponsor Trial Information Trial Location(s) and Contact(s):	Prostate Oncologic Therapy While Ensuring Neurovascular Conservation (POTEN-C) Number: NCT03525262 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Texas Southwestern Medical Center\|Boston Scientific Corporation Sponsor Trial Information Trial Location(s) and Contact(s):
Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery Number: NCT03541928 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): The Methodist Hospital Research Institute Sponsor Trial Information Trial Location(s) and Contact(s):	Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy Number: NCT03543189 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): H. Lee Moffitt Cancer Center and Research Institute\|Bristol-Myers Squibb Sponsor Trial Information Trial Location(s) and Contact(s):
BEACON: HDR Brachytherapy, EBRT and STAD for the Treatment of Local and Pelvic Recurrence of Prostate Cancer After Radiation Therapy Number: NCT03553602 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Loyola University Sponsor Trial Information Trial Location(s) and Contact(s):	Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma Number: NCT03556228 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): VM Oncology, LLC Sponsor Trial Information Trial Location(s) and Contact(s):
Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma Number: NCT03556228 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): VM Oncology, LLC Sponsor Trial Information Trial Location(s) and Contact(s):	Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma Number: NCT03556228 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): VM Oncology, LLC Sponsor Trial Information Trial Location(s) and Contact(s):
Study to Evaluate CCS1477 in Advanced Tumours Number: NCT03568656 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): CellCentric Ltd. Sponsor Trial Information Trial Location(s) and Contact(s):	Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients Number: NCT03569280 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Kangpu Biopharmaceuticals, Ltd. Sponsor Trial Information Trial Location(s) and Contact(s):
Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients Number: NCT03569280 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Kangpu Biopharmaceuticals, Ltd. Sponsor Trial Information Trial Location(s) and Contact(s):	A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer Number: NCT03574571 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Memorial Sloan Kettering Cancer Center\|Bayer Sponsor Trial Information Trial Location(s) and Contact(s):
A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer Number: NCT03574571 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Memorial Sloan Kettering Cancer Center\|Bayer Sponsor Trial Information Trial Location(s) and Contact(s):	Vitamin B6 in Reducing Hot Flashes in Participants With Prostate Cancer Undergoing Antiandrogen Therapy Number: NCT03580499 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Sidney Kimmel Cancer Center at Thomas Jefferson University\|Thomas Jefferson University Sponsor Trial Information Trial Location(s) and Contact(s):
Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate Number: NCT03582475 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Jonsson Comprehensive Cancer Center\|Merck Sharp & Dohme LLC Sponsor Trial Information Trial Location(s) and Contact(s):	Developing an Imaging-Based Tool to Identify Areas for Prostate Cancer Biopsy Number: NCT03585660 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
A Phase I/II Study of OBI-3424 in Subjects With Advanced Solid Tumors Number: NCT03592264 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): OBI Pharma, Inc Sponsor Trial Information Trial Location(s) and Contact(s):	A Phase I/II Study of OBI-3424 in Subjects With Advanced Solid Tumors Number: NCT03592264 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): OBI Pharma, Inc Sponsor Trial Information Trial Location(s) and Contact(s):
Assessment of Multi-Modality Quantitative Imaging for Evaluation of Response of Metastatic Prostate Cancer to Therapy Number: NCT03619655 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	Dose-Escalated Proton Radiation Therapy for High-Risk Prostate Cancer Number: NCT03624660 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer Number: NCT03637543 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Beth Israel Deaconess Medical Center\|Bristol-Myers Squibb\|Dana-Farber Cancer Institute Sponsor Trial Information Trial Location(s) and Contact(s):	Soy Bread Diet in Improving Immune Function in Participants With Prostate Cancer Number: NCT03654638 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Ohio State University Comprehensive Cancer Center\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
Soy Bread Diet in Improving Immune Function in Participants With Prostate Cancer Number: NCT03654638 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Ohio State University Comprehensive Cancer Center\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	Soy Bread Diet in Improving Immune Function in Participants With Prostate Cancer Number: NCT03654638 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Ohio State University Comprehensive Cancer Center\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
CivaSheet With Radical Prostatectomy & Adjuvant External Beam Radiation Number: NCT03657108 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	CivaSheet With Radical Prostatectomy & Adjuvant External Beam Radiation Number: NCT03657108 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
PRE-ProstAtectomy MRI-GuidEd Stereotactic Body RadioTherapy for High-Risk Prostate Cancer Trial (PREPARE SBRT) Number: NCT03663218 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Weill Medical College of Cornell University Sponsor Trial Information Trial Location(s) and Contact(s):	PRE-ProstAtectomy MRI-GuidEd Stereotactic Body RadioTherapy for High-Risk Prostate Cancer Trial (PREPARE SBRT) Number: NCT03663218 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Weill Medical College of Cornell University Sponsor Trial Information Trial Location(s) and Contact(s):
Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer Number: NCT03674814 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): University of Chicago\|Corcept Therapeutics\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer Number: NCT03678025 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Southwest Oncology Group\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
Carbohydrate Restricted Diet Intervention for Men on Prostate Cancer Active Surveillance Number: NCT03679260 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Cedars-Sinai Medical Center Sponsor Trial Information Trial Location(s) and Contact(s):	Multiparametric MRI in Evaluating Cancer Stage and Helping Treatment Planning in Patients With Prostate Cancer Number: NCT03697148 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Multiparametric MRI in Evaluating Cancer Stage and Helping Treatment Planning in Patients With Prostate Cancer Number: NCT03697148 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	4-aminopyridine Treatment for Nerve Injury Number: NCT03701581 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2\|Phase 3 Sponsor(s): University of Rochester\|Milton S. Hershey Medical Center Sponsor Trial Information Trial Location(s) and Contact(s):
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer Number: NCT03706365 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2\|Phase 3 Sponsor(s): Eli Lilly and Company Sponsor Trial Information Trial Location(s) and Contact(s):	Improving Quality of Life of Prostate Cancer Survivors With Androgen Deficiency Number: NCT03716739 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Dana-Farber Cancer Institute\|National Institute on Aging (NIA) Sponsor Trial Information Trial Location(s) and Contact(s):
IMMU-132 in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy Number: NCT03725761 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Wisconsin, Madison\|National Cancer Institute (NCI)\|Gilead Sciences Sponsor Trial Information Trial Location(s) and Contact(s):	Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer Number: NCT03737370 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Tufts Medical Center\|Bayer\|Lahey Clinic\|Henry Ford Hospital\|Ohio State University Comprehensive Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s):
Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer Number: NCT03753243 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Mark Garzotto, MD\|Merck Sharp & Dohme LLC\|Astellas Pharma Inc\|Portland VA Medical Center Sponsor Trial Information Trial Location(s) and Contact(s):	Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes Number: NCT03762759 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Emory University\|Telix International Pty Ltd\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy Number: NCT03767244 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Janssen Research & Development, LLC Sponsor Trial Information Trial Location(s) and Contact(s):	Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance Number: NCT03769766 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): University of Texas Southwestern Medical Center Sponsor Trial Information Trial Location(s) and Contact(s):
Methylphenidate and Exercise in Reducing Cancer-Related Fatigue in Patients With Prostate Cancer Number: NCT03772834 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2\|Phase 3 Sponsor(s): M.D. Anderson Cancer Center\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer Number: NCT03775525 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Genzada Pharmaceuticals USA, Inc.\|Translational Drug Development Sponsor Trial Information Trial Location(s) and Contact(s):
Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer Number: NCT03775525 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Genzada Pharmaceuticals USA, Inc.\|Translational Drug Development Sponsor Trial Information Trial Location(s) and Contact(s):	Conventional ADT w/ or w/Out Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT Number: NCT03777982 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Dana-Farber Cancer Institute\|Janssen Scientific Affairs, LLC Sponsor Trial Information Trial Location(s) and Contact(s):
SOR-C13 in Treating Patients With Advanced Refractory Solid Tumors Number: NCT03784677 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): M.D. Anderson Cancer Center\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	SOR-C13 in Treating Patients With Advanced Refractory Solid Tumors Number: NCT03784677 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): M.D. Anderson Cancer Center\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
SOR-C13 in Treating Patients With Advanced Refractory Solid Tumors Number: NCT03784677 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): M.D. Anderson Cancer Center\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer Number: NCT03796767 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Utah Sponsor Trial Information Trial Location(s) and Contact(s):
HoLEP Prior to Radiation Therapy for Patients With LUTS/Retention and Concurrent Prostate Cancer Number: NCT03802851 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	The Effect of Deep Versus Moderate Muscle Relaxants in Men During and After Robotic Surgery for Prostate Cancer Number: NCT03808077 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Memorial Sloan Kettering Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s):
The Effect of Deep Versus Moderate Muscle Relaxants in Men During and After Robotic Surgery for Prostate Cancer Number: NCT03808077 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Memorial Sloan Kettering Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s):	A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery Number: NCT03809000 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): RTOG Foundation, Inc.\|Pfizer\|Astellas Pharma Inc Sponsor Trial Information Trial Location(s) and Contact(s):
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy Number: NCT03821246 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Lawrence Fong\|Genentech, Inc.\|University of California, San Francisco Sponsor Trial Information Trial Location(s) and Contact(s):	Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer Number: NCT03821792 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): M.D. Anderson Cancer Center\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
CyberKnife Dose Escalation Prostate Cancer Trial Number: NCT03822494 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	WALNUTS for POWER: Polyphenols, Omega-3 Fatty Acids, Weight Loss, and EneRgy Number: NCT03824652 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Stephen Freedland\|California Walnut Commission\|Cedars-Sinai Medical Center Sponsor Trial Information Trial Location(s) and Contact(s):
WALNUTS for POWER: Polyphenols, Omega-3 Fatty Acids, Weight Loss, and EneRgy Number: NCT03824652 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Stephen Freedland\|California Walnut Commission\|Cedars-Sinai Medical Center Sponsor Trial Information Trial Location(s) and Contact(s):	WALNUTS for POWER: Polyphenols, Omega-3 Fatty Acids, Weight Loss, and EneRgy Number: NCT03824652 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Stephen Freedland\|California Walnut Commission\|Cedars-Sinai Medical Center Sponsor Trial Information Trial Location(s) and Contact(s):
WALNUTS for POWER: Polyphenols, Omega-3 Fatty Acids, Weight Loss, and EneRgy Number: NCT03824652 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Stephen Freedland\|California Walnut Commission\|Cedars-Sinai Medical Center Sponsor Trial Information Trial Location(s) and Contact(s):	WALNUTS for POWER: Polyphenols, Omega-3 Fatty Acids, Weight Loss, and EneRgy Number: NCT03824652 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Stephen Freedland\|California Walnut Commission\|Cedars-Sinai Medical Center Sponsor Trial Information Trial Location(s) and Contact(s):
WALNUTS for POWER: Polyphenols, Omega-3 Fatty Acids, Weight Loss, and EneRgy Number: NCT03824652 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Stephen Freedland\|California Walnut Commission\|Cedars-Sinai Medical Center Sponsor Trial Information Trial Location(s) and Contact(s):	WALNUTS for POWER: Polyphenols, Omega-3 Fatty Acids, Weight Loss, and EneRgy Number: NCT03824652 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Stephen Freedland\|California Walnut Commission\|Cedars-Sinai Medical Center Sponsor Trial Information Trial Location(s) and Contact(s):
Effect of Perioperative Intravenous Lidocaine Infusion in Robotic-Assisted Urologic Surgery Number: NCT03824808 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 4 Sponsor(s): University of Missouri-Columbia Sponsor Trial Information Trial Location(s) and Contact(s):	Effect of Perioperative Intravenous Lidocaine Infusion in Robotic-Assisted Urologic Surgery Number: NCT03824808 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 4 Sponsor(s): University of Missouri-Columbia Sponsor Trial Information Trial Location(s) and Contact(s):
Effect of Perioperative Intravenous Lidocaine Infusion in Robotic-Assisted Urologic Surgery Number: NCT03824808 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 4 Sponsor(s): University of Missouri-Columbia Sponsor Trial Information Trial Location(s) and Contact(s):	Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer Number: NCT03833921 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Martha Mims\|Baylor College of Medicine Sponsor Trial Information Trial Location(s) and Contact(s):
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors Number: NCT03845166 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Exelixis Sponsor Trial Information Trial Location(s) and Contact(s):	HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Number: NCT03850795 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Hinova Pharmaceuticals USA, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):
HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Number: NCT03850795 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Hinova Pharmaceuticals USA, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):	Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer Number: NCT03860987 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s):
Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer Number: NCT03860987 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s):	Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors Number: NCT03866382 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors Number: NCT03866382 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer Number: NCT03873805 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): City of Hope Medical Center\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Number: NCT03878524 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): OHSU Knight Cancer Institute\|Oregon Health and Science University Sponsor Trial Information Trial Location(s) and Contact(s):	Nutrition and Exercise Interventions in Reducing Androgen Deprivation Therapy-Induced Obese Frailty in Prostate Cancer Survivors Number: NCT03880422 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer Number: NCT03888612 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Arvinas Androgen Receptor, Inc.\|Arvinas Inc. Sponsor Trial Information Trial Location(s) and Contact(s):	Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer Number: NCT03888612 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Arvinas Androgen Receptor, Inc.\|Arvinas Inc. Sponsor Trial Information Trial Location(s) and Contact(s):
the Safety and Tolerability of Proxalutamide (GT0918) in Subjects With Metastatic Castrate Resistant Prostate Cancer Number: NCT03899467 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Suzhou Kintor Pharmaceutical Inc, Sponsor Trial Information Trial Location(s) and Contact(s):	the Safety and Tolerability of Proxalutamide (GT0918) in Subjects With Metastatic Castrate Resistant Prostate Cancer Number: NCT03899467 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Suzhou Kintor Pharmaceutical Inc, Sponsor Trial Information Trial Location(s) and Contact(s):
Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery Number: NCT03899987 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Roswell Park Cancer Institute\|AIM ImmunoTech Inc. Sponsor Trial Information Trial Location(s) and Contact(s):	Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer Number: NCT03902951 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Jonsson Comprehensive Cancer Center\|Janssen Inc. Sponsor Trial Information Trial Location(s) and Contact(s):
A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype. Number: NCT03910660 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): BioXcel Therapeutics Inc Sponsor Trial Information Trial Location(s) and Contact(s):	CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone Number: NCT03934840 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Masonic Cancer Center, University of Minnesota Sponsor Trial Information Trial Location(s) and Contact(s):
CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone Number: NCT03934840 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Masonic Cancer Center, University of Minnesota Sponsor Trial Information Trial Location(s) and Contact(s):	Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer Number: NCT03972657 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Regeneron Pharmaceuticals Sponsor Trial Information Trial Location(s) and Contact(s):
Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer Number: NCT03972657 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Regeneron Pharmaceuticals Sponsor Trial Information Trial Location(s) and Contact(s):	Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer Number: NCT03976843 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s):
Resistance Training +/- Creatine for Metastatic Prostate Cancer Patients Number: NCT03987217 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): University of Utah\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer Number: NCT03987386 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): M.D. Anderson Cancer Center\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
Hydroxychloroquine to Increase Tumor Suppressor PAR-4 Levels in Oligometastatic Prostate Cancer Number: NCT04011410 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Andrew C. James, MD\|University of Kentucky Sponsor Trial Information Trial Location(s) and Contact(s):	A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer Number: NCT04019327 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Memorial Sloan Kettering Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s):
Nivolumab in Biochemically Recurrent dMMR Prostate Cancer Number: NCT04019964 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|Bristol-Myers Squibb Sponsor Trial Information Trial Location(s) and Contact(s):	INTREPId (INTermediate Risk Erection PreservatIon Trial) Number: NCT04025372 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Dana-Farber Cancer Institute\|Bayer\|Decipher Biosciences Sponsor Trial Information Trial Location(s) and Contact(s):
Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects Number: NCT04030559 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of California, Davis\|National Cancer Institute (NCI)\|Janssen, LP Sponsor Trial Information Trial Location(s) and Contact(s):	A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors Number: NCT04032704 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Seagen Inc. Sponsor Trial Information Trial Location(s) and Contact(s):
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors Number: NCT04032704 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Seagen Inc. Sponsor Trial Information Trial Location(s) and Contact(s):	RAdium-223 and SABR Versus SABR for Oligometastatic Prostate Cancers Number: NCT04037358 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Sponsor Trial Information Trial Location(s) and Contact(s):
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer Number: NCT04038502 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): VA Office of Research and Development Sponsor Trial Information Trial Location(s) and Contact(s):	Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC Number: NCT04060394 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Laekna Limited Sponsor Trial Information Trial Location(s) and Contact(s):
Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC Number: NCT04060394 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Laekna Limited Sponsor Trial Information Trial Location(s) and Contact(s):	OPTimizing Treatment Focused Genetic Testing IN Cancer Number: NCT04066361 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy Number: NCT04068896 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): NGM Biopharmaceuticals, Inc Sponsor Trial Information Trial Location(s) and Contact(s):	Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormo Number: NCT04071236 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer Number: NCT04090528 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Wisconsin, Madison\|Merck Sharp & Dohme LLC\|Madison Vaccines, Inc\|Prostate Cancer Foundation Sponsor Trial Information Trial Location(s) and Contact(s):	pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer Number: NCT04090528 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Wisconsin, Madison\|Merck Sharp & Dohme LLC\|Madison Vaccines, Inc\|Prostate Cancer Foundation Sponsor Trial Information Trial Location(s) and Contact(s):
A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer Number: NCT04100018 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Bristol-Myers Squibb Sponsor Trial Information Trial Location(s) and Contact(s):	A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas Number: NCT04104776 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Constellation Pharmaceuticals Sponsor Trial Information Trial Location(s) and Contact(s):
A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation Number: NCT04104893 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): VA Office of Research and Development\|Merck Sharp & Dohme LLC Sponsor Trial Information Trial Location(s) and Contact(s):	A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation Number: NCT04104893 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): VA Office of Research and Development\|Merck Sharp & Dohme LLC Sponsor Trial Information Trial Location(s) and Contact(s):
Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer Number: NCT04109729 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): University of Utah Sponsor Trial Information Trial Location(s) and Contact(s):	Stereotactic Magnetic Resonance Guided Radiation Therapy Number: NCT04115254 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Stereotactic Magnetic Resonance Guided Radiation Therapy Number: NCT04115254 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer. Number: NCT04116775 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Julie Graff, MD\|Merck Sharp & Dohme LLC\|Prostate Cancer Foundation\|Johns Hopkins University\|Oregon Health and Science University\|Portland VA Medical Center Sponsor Trial Information Trial Location(s) and Contact(s):
Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer. Number: NCT04116775 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Julie Graff, MD\|Merck Sharp & Dohme LLC\|Prostate Cancer Foundation\|Johns Hopkins University\|Oregon Health and Science University\|Portland VA Medical Center Sponsor Trial Information Trial Location(s) and Contact(s):	A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described Number: NCT04122976 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Sponsor(s): Bayer Sponsor Trial Information Trial Location(s) and Contact(s):
Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors Number: NCT04126070 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Xiao X. Wei\|Bristol-Myers Squibb\|Dana-Farber Cancer Institute Sponsor Trial Information Trial Location(s) and Contact(s):	Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer Number: NCT04134260 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): NRG Oncology\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate Number: NCT04136353 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): University of Sydney\|Australian and New Zealand Urogenital and Prostate Cancer Trials Group\|Bayer\|Cancer Trials Ireland\|Canadian Cancer Trials Group\|Memorial Sloan Kettering Cancer Center\|Prostate Cancer Clinical Trials Consortium Sponsor Trial Information Trial Location(s) and Contact(s):	Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC Number: NCT04140526 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): OncoC4, Inc.\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
A Pilot Study of Ultra-High-Dose Hypofractionated or Single-Dose Radiotherapy for Intermediate Risk Prostate Cancer Number: NCT04147806 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Albert Einstein College of Medicine Sponsor Trial Information Trial Location(s) and Contact(s):	18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies Number: NCT04158245 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Tulane University\|Blue Earth Diagnostics Sponsor Trial Information Trial Location(s) and Contact(s):
18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies Number: NCT04158245 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Tulane University\|Blue Earth Diagnostics Sponsor Trial Information Trial Location(s) and Contact(s):	The Use of Nanoparticles to Guide the Surgical Treatment of Prostate Cancer Number: NCT04167969 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Memorial Sloan Kettering Cancer Center\|Elucida Oncology\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
Fluciclovine (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study Number: NCT04175431 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Washington\|Blue Earth Diagnostics Sponsor Trial Information Trial Location(s) and Contact(s):	CELLO-1, Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Subjects With Castration Resistant Prostate Cancer Who Have Not Received Chemotherapy Number: NCT04179864 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Epizyme, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):
CELLO-1, Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Subjects With Castration Resistant Prostate Cancer Who Have Not Received Chemotherapy Number: NCT04179864 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Epizyme, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):	The Role of 68Gallium PSMA-11 in Enhancing Diagnosis of Primary and Metastatic Prostate Cancer Number: NCT04179968 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Dana Mathews\|University of Texas Southwestern Medical Center Sponsor Trial Information Trial Location(s) and Contact(s):
Study of NMS-03305293 in Pts With Selected Advanced/Metastatic Solid Tumors Number: NCT04182516 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Nerviano Medical Sciences Sponsor Trial Information Trial Location(s) and Contact(s):	Study of NMS-03305293 in Pts With Selected Advanced/Metastatic Solid Tumors Number: NCT04182516 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Nerviano Medical Sciences Sponsor Trial Information Trial Location(s) and Contact(s):
Serial MRI Scans During Radiation Therapy Number: NCT04188535 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer Number: NCT04194554 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): University of Michigan Rogel Cancer Center\|Janssen Scientific Affairs, LLC Sponsor Trial Information Trial Location(s) and Contact(s):
A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer Number: NCT04194554 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): University of Michigan Rogel Cancer Center\|Janssen Scientific Affairs, LLC Sponsor Trial Information Trial Location(s) and Contact(s):	Radium-223 in Biochemically Recurrent Prostate Cancer Number: NCT04206319 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s):
Radium-223 in Biochemically Recurrent Prostate Cancer Number: NCT04206319 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s):	Addition of Opaganib to Androgen Antagonists in Patients With mCRPC Number: NCT04207255 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Medical University of South Carolina\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
Addition of Opaganib to Androgen Antagonists in Patients With mCRPC Number: NCT04207255 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Medical University of South Carolina\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	PRAGMA (Prostate Radio Ablation Guided by Magnetic Resonance Imaging Acquisition) in Metastatic Prostate Cancer Number: NCT04220983 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Weill Medical College of Cornell University Sponsor Trial Information Trial Location(s) and Contact(s):
PRAGMA (Prostate Radio Ablation Guided by Magnetic Resonance Imaging Acquisition) in Metastatic Prostate Cancer Number: NCT04220983 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Weill Medical College of Cornell University Sponsor Trial Information Trial Location(s) and Contact(s):	Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer Number: NCT04221542 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Amgen Sponsor Trial Information Trial Location(s) and Contact(s):
TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer Number: NCT04246671 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Bavarian Nordic Sponsor Trial Information Trial Location(s) and Contact(s):	TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer Number: NCT04246671 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Bavarian Nordic Sponsor Trial Information Trial Location(s) and Contact(s):
P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC) Number: NCT04249947 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Poseida Therapeutics, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):	Comparison of High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy for the Treatment of Localized Prostate Cancer Number: NCT04253483 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Rutgers, The State University of New Jersey\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer Number: NCT04262154 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Memorial Sloan Kettering Cancer Center\|Genentech, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):	AMNIOX CORD Study - Radical Prostatectomy With and Without Cryopreserved Umbilical Cord Allograft Number: NCT04263025 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2\|Phase 3 Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
AMNIOX CORD Study - Radical Prostatectomy With and Without Cryopreserved Umbilical Cord Allograft Number: NCT04263025 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2\|Phase 3 Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer Number: NCT04267887 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): OHSU Knight Cancer Institute\|Janssen Scientific Affairs, LLC\|Oregon Health and Science University Sponsor Trial Information Trial Location(s) and Contact(s):
ATR Inhibitor BAY 1895344 Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer Number: NCT04267939 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Bayer Sponsor Trial Information Trial Location(s) and Contact(s):	A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects Number: NCT04288687 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Abramson Cancer Center of the University of Pennsylvania Sponsor Trial Information Trial Location(s) and Contact(s):
PK and Dose Escalation and Expansion Study of DST-2970 Number: NCT04291664 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): DisperSol Technologies, LLC\|Translational Drug Development Sponsor Trial Information Trial Location(s) and Contact(s):	PK and Dose Escalation and Expansion Study of DST-2970 Number: NCT04291664 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): DisperSol Technologies, LLC\|Translational Drug Development Sponsor Trial Information Trial Location(s) and Contact(s):
Abemaciclib in Combination With Androgen Deprivation Therapy for Locally Advanced Prostate Cancer Number: NCT04298983 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Alabama at Birmingham Sponsor Trial Information Trial Location(s) and Contact(s):	Clinical Trial of Green Tea Catechins in Men on Active Surveillance Number: NCT04300855 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): H. Lee Moffitt Cancer Center and Research Institute\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer Number: NCT04301414 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): Matthew Dallos\|Bristol-Myers Squibb\|Ferring Pharmaceuticals\|Columbia University Sponsor Trial Information Trial Location(s) and Contact(s):	Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer Number: NCT04301414 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): Matthew Dallos\|Bristol-Myers Squibb\|Ferring Pharmaceuticals\|Columbia University Sponsor Trial Information Trial Location(s) and Contact(s):
An Investigational Scan (7 Tesla MRI) in Diagnosing Cognitive Impairment in Patients With Non-Metastatic Prostate Cancer Number: NCT04318028 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide Number: NCT04335682 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Alliance Foundation Trials, LLC.\|Bayer Sponsor Trial Information Trial Location(s) and Contact(s):
Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide Number: NCT04335682 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Alliance Foundation Trials, LLC.\|Bayer Sponsor Trial Information Trial Location(s) and Contact(s):	Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load Number: NCT04336943 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Washington\|AstraZeneca Sponsor Trial Information Trial Location(s) and Contact(s):
Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer Number: NCT04337580 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Wake Forest University Health Sciences\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer Number: NCT04337580 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Wake Forest University Health Sciences\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
Magnetic Resonance Imaging (MRI) With Hyperpolarized Pyruvate (13C) as Diagnostic Tool in Advanced Prostate Cancer Number: NCT04346225 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Rahul Aggarwal\|National Cancer Institute (NCI)\|University of California, San Francisco Sponsor Trial Information Trial Location(s) and Contact(s):	Biomarker Monitoring of Prostate Cancer Patients With RSI MRI (ProsRSI) Number: NCT04349501 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of California, San Diego Sponsor Trial Information Trial Location(s) and Contact(s):
Biomarker Monitoring of Prostate Cancer Patients With RSI MRI (ProsRSI) Number: NCT04349501 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of California, San Diego Sponsor Trial Information Trial Location(s) and Contact(s):	Biomarker Monitoring of Prostate Cancer Patients With RSI MRI (ProsRSI) Number: NCT04349501 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of California, San Diego Sponsor Trial Information Trial Location(s) and Contact(s):
Biomarker Monitoring of Prostate Cancer Patients With RSI MRI (ProsRSI) Number: NCT04349501 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of California, San Diego Sponsor Trial Information Trial Location(s) and Contact(s):	Biomarker Monitoring of Prostate Cancer Patients With RSI MRI (ProsRSI) Number: NCT04349501 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of California, San Diego Sponsor Trial Information Trial Location(s) and Contact(s):
Biomarker Monitoring of Prostate Cancer Patients With RSI MRI (ProsRSI) Number: NCT04349501 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of California, San Diego Sponsor Trial Information Trial Location(s) and Contact(s):	Biomarker Monitoring of Prostate Cancer Patients With RSI MRI (ProsRSI) Number: NCT04349501 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of California, San Diego Sponsor Trial Information Trial Location(s) and Contact(s):
Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression Number: NCT04363164 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|United States Department of Defense Sponsor Trial Information Trial Location(s) and Contact(s):	Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression Number: NCT04363164 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|United States Department of Defense Sponsor Trial Information Trial Location(s) and Contact(s):
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years Number: NCT04373564 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 4 Sponsor(s): Guerbet\|Bayer AG (Sponsor)\|Bracco (Sponsor)\|GEHC (Sponsor) Sponsor Trial Information Trial Location(s) and Contact(s):	Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer Number: NCT04381832 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Arcus Biosciences, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer Number: NCT04381832 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Arcus Biosciences, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):	Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Number: NCT04383210 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Elevation Oncology Sponsor Trial Information Trial Location(s) and Contact(s):
DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers Number: NCT04388852 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): M.D. Anderson Cancer Center\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	18F-DCFPyL PET/CT Impact on Treatment Strategies for Patients With Prostate Cancer Number: NCT04390880 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): VA Greater Los Angeles Healthcare System Sponsor Trial Information Trial Location(s) and Contact(s):
The Impact of Low Pressure Pneumo in RARP II Number: NCT04394676 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer Number: NCT04396808 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer Number: NCT04402151 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Weill Medical College of Cornell University\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	Oral EPI-7386 in Patients With Castration-Resistant Prostate Cancer Number: NCT04421222 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): ESSA Pharmaceuticals Sponsor Trial Information Trial Location(s) and Contact(s):
Randomized Phase II Trial of Salvage Radiotherapy for Prostate Cancer In 4 Weeks v. 2 Weeks Number: NCT04422132 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Weill Medical College of Cornell University\|Viewray Inc. Sponsor Trial Information Trial Location(s) and Contact(s):	A Study to Assess DF6002 (BMS-986415) Alone and in Combination With Nivolumab in Participants With Locally Advanced or Metastatic Solid Tumors Number: NCT04423029 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Bristol-Myers Squibb Sponsor Trial Information Trial Location(s) and Contact(s):
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Using PET/CT Imaging Number: NCT04423211 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): ECOG-ACRIN Cancer Research Group\|National Cancer Institute (NCI)\|Eastern Cooperative Oncology Group Sponsor Trial Information Trial Location(s) and Contact(s):	Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer Number: NCT04428788 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Celgene Sponsor Trial Information Trial Location(s) and Contact(s):
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC Number: NCT04446117 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Exelixis\|Roche-Genentech\|Takeda Sponsor Trial Information Trial Location(s) and Contact(s):	Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC Number: NCT04446117 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Exelixis\|Roche-Genentech\|Takeda Sponsor Trial Information Trial Location(s) and Contact(s):
A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy Number: NCT04455750 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	Prospective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology Validation Number: NCT04457232 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Jonsson Comprehensive Cancer Center\|Prostate Cancer Foundation Sponsor Trial Information Trial Location(s) and Contact(s):
Prospective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology Validation Number: NCT04457232 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Jonsson Comprehensive Cancer Center\|Prostate Cancer Foundation Sponsor Trial Information Trial Location(s) and Contact(s):	High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy Number: NCT04461509 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Alessandro D'Agnolo\|Progenics Pharmaceuticals, Inc.\|Cedars-Sinai Medical Center Sponsor Trial Information Trial Location(s) and Contact(s):
EBRT and HDR Brachytherapy for Unfavorable-intermediate, High, and Very High-risk Prostate Cancer Number: NCT04465500 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Virginia Sponsor Trial Information Trial Location(s) and Contact(s):	EBRT and HDR Brachytherapy for Unfavorable-intermediate, High, and Very High-risk Prostate Cancer Number: NCT04465500 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Virginia Sponsor Trial Information Trial Location(s) and Contact(s):
Study in Patients With Advanced Cancers Associated With Expression of DLL3 Who Have Failed Standard Available Therapy Number: NCT04471727 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Harpoon Therapeutics Sponsor Trial Information Trial Location(s) and Contact(s):	Study in Patients With Advanced Cancers Associated With Expression of DLL3 Who Have Failed Standard Available Therapy Number: NCT04471727 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Harpoon Therapeutics Sponsor Trial Information Trial Location(s) and Contact(s):
ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer Number: NCT04471974 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Rahul Aggarwal\|Zenith Epigenetics\|Merck Sharp & Dohme LLC\|U.S. Army Medical Research and Development Command\|University of California, San Francisco Sponsor Trial Information Trial Location(s) and Contact(s):	ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer Number: NCT04471974 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Rahul Aggarwal\|Zenith Epigenetics\|Merck Sharp & Dohme LLC\|U.S. Army Medical Research and Development Command\|University of California, San Francisco Sponsor Trial Information Trial Location(s) and Contact(s):
Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial) Number: NCT04477512 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Washington University School of Medicine\|Bristol-Myers Squibb\|Exelixis Sponsor Trial Information Trial Location(s) and Contact(s):	A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors Number: NCT04478279 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Sapience Therapeutics Sponsor Trial Information Trial Location(s) and Contact(s):
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors Number: NCT04478279 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Sapience Therapeutics Sponsor Trial Information Trial Location(s) and Contact(s):	68Ga PSMA-11 PET/CT in Recurrent Prostate Cancer Number: NCT04483414 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Dana Mathews\|University of Texas Southwestern Medical Center Sponsor Trial Information Trial Location(s) and Contact(s):
Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study Number: NCT04484818 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): ECOG-ACRIN Cancer Research Group\|National Cancer Institute (NCI)\|Eastern Cooperative Oncology Group Sponsor Trial Information Trial Location(s) and Contact(s):	TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers Number: NCT04485013 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Tizona Therapeutics, Inc Sponsor Trial Information Trial Location(s) and Contact(s):
Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048) Number: NCT04486755 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): University of Maryland, Baltimore Sponsor Trial Information Trial Location(s) and Contact(s):	Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048) Number: NCT04486755 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): University of Maryland, Baltimore Sponsor Trial Information Trial Location(s) and Contact(s):
Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048) Number: NCT04486755 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): University of Maryland, Baltimore Sponsor Trial Information Trial Location(s) and Contact(s):	Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency Number: NCT04493853 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): AstraZeneca Sponsor Trial Information Trial Location(s) and Contact(s):
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Number: NCT04497844 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Janssen Research & Development, LLC Sponsor Trial Information Trial Location(s) and Contact(s):	A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies Number: NCT04503265 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): AtlasMedx, Incorporated Sponsor Trial Information Trial Location(s) and Contact(s):
Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC Number: NCT04506567 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Weill Medical College of Cornell University Sponsor Trial Information Trial Location(s) and Contact(s):	Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial Number: NCT04513717 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): NRG Oncology\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial Number: NCT04513717 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): NRG Oncology\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Number: NCT04514484 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Number: NCT04514484 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	White Button Mushroom Sup for the Reduction of PSA in Pts With Biochemically Rec or Therapy Naive Fav Risk Prostate CA Number: NCT04519879 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): City of Hope Medical Center\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
White Button Mushroom Sup for the Reduction of PSA in Pts With Biochemically Rec or Therapy Naive Fav Risk Prostate CA Number: NCT04519879 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): City of Hope Medical Center\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations Number: NCT04521686 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Eli Lilly and Company\|Loxo Oncology, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations Number: NCT04521686 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Eli Lilly and Company\|Loxo Oncology, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):	[18F]FLOR (FC303) PET/CT Imaging in Patients With Prostate Cancer Number: NCT04528199 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|FutureChem Sponsor Trial Information Trial Location(s) and Contact(s):
[18F]FLOR (FC303) PET/CT Imaging in Patients With Prostate Cancer Number: NCT04528199 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|FutureChem Sponsor Trial Information Trial Location(s) and Contact(s):	Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland Number: NCT04530552 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland Number: NCT04530552 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland Number: NCT04530552 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
Jump: MR Simulation For Radiation Therapy Master Protocol Number: NCT04545957 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	Jump: MR Simulation For Radiation Therapy Master Protocol Number: NCT04545957 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations Number: NCT04550494 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	TRUEBEAM Stereotactic Body Radiotherapy for Localized Prostate Cancer Number: NCT04552509 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
TRUEBEAM Stereotactic Body Radiotherapy for Localized Prostate Cancer Number: NCT04552509 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Prostate-Specific Membrane Antigen-Positron Emission Tomography (PSMA-PET) Positive Hormone-Sensitive Prostate Cancer Participants Number: NCT04557059 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors Number: NCT04557449 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Pfizer Sponsor Trial Information Trial Location(s) and Contact(s):	A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer Number: NCT04564027 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): AstraZeneca Sponsor Trial Information Trial Location(s) and Contact(s):
A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer Number: NCT04564027 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): AstraZeneca Sponsor Trial Information Trial Location(s) and Contact(s):	Prostate Imaging Using MRI +/- Contrast Enhancement Number: NCT04571840 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Prostate Imaging Using MRI +/- Contrast Enhancement Number: NCT04571840 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	A Study of FT-7051 in Men With MCRPC Number: NCT04575766 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Forma Therapeutics, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):
Re-treatment 225Ac-J591 for mCRPC Number: NCT04576871 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): Weill Medical College of Cornell University Sponsor Trial Information Trial Location(s) and Contact(s):	INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors Number: NCT04580485 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Incyte Corporation Sponsor Trial Information Trial Location(s) and Contact(s):
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Number: NCT04586335 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Haihe Biopharma Co., Ltd. Sponsor Trial Information Trial Location(s) and Contact(s):	Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Number: NCT04586335 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Haihe Biopharma Co., Ltd. Sponsor Trial Information Trial Location(s) and Contact(s):
Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer Number: NCT04592237 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): M.D. Anderson Cancer Center\|Janssen Pharmaceutica Sponsor Trial Information Trial Location(s) and Contact(s):	Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer Number: NCT04592237 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): M.D. Anderson Cancer Center\|Janssen Pharmaceutica Sponsor Trial Information Trial Location(s) and Contact(s):
To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring Number: NCT04597359 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): ECOG-ACRIN Cancer Research Group\|National Cancer Institute (NCI)\|Eastern Cooperative Oncology Group Sponsor Trial Information Trial Location(s) and Contact(s):	To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring Number: NCT04597359 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): ECOG-ACRIN Cancer Research Group\|National Cancer Institute (NCI)\|Eastern Cooperative Oncology Group Sponsor Trial Information Trial Location(s) and Contact(s):
To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring Number: NCT04597359 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): ECOG-ACRIN Cancer Research Group\|National Cancer Institute (NCI)\|Eastern Cooperative Oncology Group Sponsor Trial Information Trial Location(s) and Contact(s):	Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer Number: NCT04600336 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer Number: NCT04600336 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer Number: NCT04600336 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer Number: NCT04600336 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	Study of PF-07248144 in Advanced or Metastatic Solid Tumors Number: NCT04606446 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Pfizer Sponsor Trial Information Trial Location(s) and Contact(s):
Study of PF-07248144 in Advanced or Metastatic Solid Tumors Number: NCT04606446 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Pfizer Sponsor Trial Information Trial Location(s) and Contact(s):	Study of PF-07248144 in Advanced or Metastatic Solid Tumors Number: NCT04606446 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Pfizer Sponsor Trial Information Trial Location(s) and Contact(s):
Germline DNA-Based Radiosensitivity Biomarker Influence on Toxicity Following Prostate Radiotherapy, GARUDA Trial Number: NCT04624256 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	A Study of CC-90011 and Comparators in Participants With Prostate Cancer Number: NCT04628988 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Celgene Sponsor Trial Information Trial Location(s) and Contact(s):
Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC) Number: NCT04631744 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Weill Medical College of Cornell University\|Exelixis Sponsor Trial Information Trial Location(s) and Contact(s):	M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer Number: NCT04633252 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s):
M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer Number: NCT04633252 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s):	Pacritinib for Biochemical Relapse After Definitive Treatment for Prostate Cancer Number: NCT04635059 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Medical College of Wisconsin Sponsor Trial Information Trial Location(s) and Contact(s):
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies Number: NCT04644068 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): AstraZeneca Sponsor Trial Information Trial Location(s) and Contact(s):	Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies Number: NCT04644068 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): AstraZeneca Sponsor Trial Information Trial Location(s) and Contact(s):
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies Number: NCT04644068 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): AstraZeneca Sponsor Trial Information Trial Location(s) and Contact(s):	A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer Number: NCT04644770 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Janssen Research & Development, LLC Sponsor Trial Information Trial Location(s) and Contact(s):
A Study of Focal Salvage High-Dose-Rate Brachytherapy for Prostate Gland Only Recurrence Number: NCT04645810 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): University of Rochester Sponsor Trial Information Trial Location(s) and Contact(s):	Brain and Pelvic Floor Muscle Activity of Patients Undergoing Robot-Assisted Radical Prostatectomy Number: NCT04646434 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Brain and Pelvic Floor Muscle Activity of Patients Undergoing Robot-Assisted Radical Prostatectomy Number: NCT04646434 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment Number: NCT04647526 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): POINT Biopharma Sponsor Trial Information Trial Location(s) and Contact(s):
Preliminary Effectiveness of Focal US-guided Cryo-ablation Using DynaCAD / UroNAV Preplanning / Guidance of Locally Confined Intermediate Risk Prostate Cancer Number: NCT04656678 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	Insulin Resistance Following ADT for Prostate CA Number: NCT04658849 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): St. Louis University Sponsor Trial Information Trial Location(s) and Contact(s):
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors Number: NCT04660929 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Carisma Therapeutics Inc Sponsor Trial Information Trial Location(s) and Contact(s):	ARX517 in Subjects With Advanced Solid Tumor Number: NCT04662580 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Ambrx, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):
ARX517 in Subjects With Advanced Solid Tumor Number: NCT04662580 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Ambrx, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):	ARX517 in Subjects With Advanced Solid Tumor Number: NCT04662580 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Ambrx, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):
Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer Number: NCT04666129 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Myovant Sciences GmbH Sponsor Trial Information Trial Location(s) and Contact(s):	Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer Number: NCT04666129 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Myovant Sciences GmbH Sponsor Trial Information Trial Location(s) and Contact(s):
Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer Number: NCT04666129 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Myovant Sciences GmbH Sponsor Trial Information Trial Location(s) and Contact(s):	Study of PCUR-101 in Combination With ADT in Patients With mCRPC Number: NCT04677855 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
177Lu-PSMA-617 vs. Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer Number: NCT04689828 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Novartis Pharmaceuticals\|Novartis Sponsor Trial Information Trial Location(s) and Contact(s):	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resist Number: NCT04691804 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Jiangsu HengRui Medicine Co., Ltd. Sponsor Trial Information Trial Location(s) and Contact(s):
Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer Number: NCT04692675 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial Number: NCT04693377 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Single-Port Versus Multi-Port Robotic Radical Prostatectomy Number: NCT04696263 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging Number: NCT04698564 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Maryland, Baltimore Sponsor Trial Information Trial Location(s) and Contact(s):
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging Number: NCT04698564 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Maryland, Baltimore Sponsor Trial Information Trial Location(s) and Contact(s):	Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging Number: NCT04698564 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Maryland, Baltimore Sponsor Trial Information Trial Location(s) and Contact(s):
PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer Number: NCT04700332 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Hoag Memorial Hospital Presbyterian Sponsor Trial Information Trial Location(s) and Contact(s):	PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer Number: NCT04700332 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Hoag Memorial Hospital Presbyterian Sponsor Trial Information Trial Location(s) and Contact(s):
A Study of Tarlatamab (AMG 757) in Participants With Neuroendocrine Prostate Cancer Number: NCT04702737 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Amgen Sponsor Trial Information Trial Location(s) and Contact(s):	Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer Number: NCT04703920 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): University of Michigan Rogel Cancer Center\|Pfizer\|Acrotech Biopharma LLC Sponsor Trial Information Trial Location(s) and Contact(s):
Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Number: NCT04704505 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Sponsor Trial Information Trial Location(s) and Contact(s):	TH1902 in Patients With Advanced Solid Tumors Number: NCT04706962 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Theratechnologies\|PPD Sponsor Trial Information Trial Location(s) and Contact(s):
TH1902 in Patients With Advanced Solid Tumors Number: NCT04706962 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Theratechnologies\|PPD Sponsor Trial Information Trial Location(s) and Contact(s):	A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer Number: NCT04709276 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Andrew J. Armstrong, MD\|Bristol-Myers Squibb\|Duke University Sponsor Trial Information Trial Location(s) and Contact(s):
A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer Number: NCT04709276 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Andrew J. Armstrong, MD\|Bristol-Myers Squibb\|Duke University Sponsor Trial Information Trial Location(s) and Contact(s):	A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer Number: NCT04709276 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Andrew J. Armstrong, MD\|Bristol-Myers Squibb\|Duke University Sponsor Trial Information Trial Location(s) and Contact(s):
A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer Number: NCT04709276 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Andrew J. Armstrong, MD\|Bristol-Myers Squibb\|Duke University Sponsor Trial Information Trial Location(s) and Contact(s):	68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer Number: NCT04716725 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of California, San Francisco\|Conquer Cancer Foundation\|Gateway for Cancer Research\|Prostate Cancer Foundation Sponsor Trial Information Trial Location(s) and Contact(s):
An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC Number: NCT04720157 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Novartis Pharmaceuticals\|Alliance Foundation Trials, LLC.\|RTOG Foundation, Inc.\|Novartis Sponsor Trial Information Trial Location(s) and Contact(s):	Proton Radiation Therapy for the Treatment of Patients With High Risk Prostate Cancer Number: NCT04725903 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Emory University\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
Proton Radiation Therapy for the Treatment of Patients With High Risk Prostate Cancer Number: NCT04725903 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Emory University\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	Proton Radiation Therapy for the Treatment of Patients With High Risk Prostate Cancer Number: NCT04725903 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Emory University\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101) Number: NCT04726332 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Exelixis Sponsor Trial Information Trial Location(s) and Contact(s):	Open-label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer Number: NCT04729114 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Propella Therapeutics Sponsor Trial Information Trial Location(s) and Contact(s):
Open-label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer Number: NCT04729114 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Propella Therapeutics Sponsor Trial Information Trial Location(s) and Contact(s):	Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer Number: NCT04731844 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Rochester Sponsor Trial Information Trial Location(s) and Contact(s):
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer Number: NCT04734730 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): City of Hope Medical Center\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer Number: NCT04734730 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): City of Hope Medical Center\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer Number: NCT04734730 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): City of Hope Medical Center\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma Number: NCT04740034 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Amgen Sponsor Trial Information Trial Location(s) and Contact(s):
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer Number: NCT04742361 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): ABX advanced biochemical compounds GmbH Sponsor Trial Information Trial Location(s) and Contact(s):	Study of TT-00420 Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors Number: NCT04742959 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): TransThera Sciences (Nanjing), Inc. Sponsor Trial Information Trial Location(s) and Contact(s):
Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer Number: NCT04743934 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Andrew McDonald\|University of Alabama at Birmingham Sponsor Trial Information Trial Location(s) and Contact(s):	Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer Number: NCT04743934 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Andrew McDonald\|University of Alabama at Birmingham Sponsor Trial Information Trial Location(s) and Contact(s):
Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer Number: NCT04743934 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Andrew McDonald\|University of Alabama at Birmingham Sponsor Trial Information Trial Location(s) and Contact(s):	Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer Number: NCT04743934 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Andrew McDonald\|University of Alabama at Birmingham Sponsor Trial Information Trial Location(s) and Contact(s):
Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer Number: NCT04743934 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Andrew McDonald\|University of Alabama at Birmingham Sponsor Trial Information Trial Location(s) and Contact(s):	Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer Number: NCT04743934 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Andrew McDonald\|University of Alabama at Birmingham Sponsor Trial Information Trial Location(s) and Contact(s):
Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer Number: NCT04743934 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Andrew McDonald\|University of Alabama at Birmingham Sponsor Trial Information Trial Location(s) and Contact(s):	Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON) Number: NCT04748042 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Michigan Rogel Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s):
Abemaciclib With or Without Atezolizumab for mCRPC Number: NCT04751929 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Dana-Farber Cancer Institute\|Eli Lilly and Company\|Genentech, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):	Enfortumab Vedotin as Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer Number: NCT04754191 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Utah\|Astellas Pharma Inc Sponsor Trial Information Trial Location(s) and Contact(s):
Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer Number: NCT04754425 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): M.D. Anderson Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s):	The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors Number: NCT04768868 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Impact Therapeutics, Inc.\|Covance Sponsor Trial Information Trial Location(s) and Contact(s):
The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors Number: NCT04768868 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Impact Therapeutics, Inc.\|Covance Sponsor Trial Information Trial Location(s) and Contact(s):	An Investigational Scan (68Ga-PSMA-11 PET/CT) for the Imaging of Prostate Cancer Number: NCT04777071 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Washington Sponsor Trial Information Trial Location(s) and Contact(s):
An Investigational Scan (68Ga-PSMA-11 PET/CT) for the Imaging of Prostate Cancer Number: NCT04777071 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Washington Sponsor Trial Information Trial Location(s) and Contact(s):	An Investigational Scan (68Ga-PSMA-11 PET/CT) for the Imaging of Prostate Cancer Number: NCT04777071 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Washington Sponsor Trial Information Trial Location(s) and Contact(s):
An Investigational Scan (68Ga-PSMA-11 PET/CT) for the Imaging of Prostate Cancer Number: NCT04777071 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Washington Sponsor Trial Information Trial Location(s) and Contact(s):	An Investigational Scan (68Ga-PSMA-11 PET/CT) for the Imaging of Prostate Cancer Number: NCT04777071 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Washington Sponsor Trial Information Trial Location(s) and Contact(s):
An Investigational Scan (68Ga-PSMA-11 PET/CT) for the Imaging of Prostate Cancer Number: NCT04777071 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Washington Sponsor Trial Information Trial Location(s) and Contact(s):	An Investigational Scan (68Ga-PSMA-11 PET/CT) for the Imaging of Prostate Cancer Number: NCT04777071 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Washington Sponsor Trial Information Trial Location(s) and Contact(s):
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for OligoRecurrenT Prostate Cancer Number: NCT04787744 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2\|Phase 3 Sponsor(s): VA Office of Research and Development Sponsor Trial Information Trial Location(s) and Contact(s):	Transperineal vs. Transrectal MRI-targeted Prostate Biopsy Number: NCT04815876 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC Number: NCT04821622 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Pfizer\|Astellas Pharma Inc Sponsor Trial Information Trial Location(s) and Contact(s):	Phase II Study of Pencil Beam Scanning Proton Stereotactic Body Radiation Therapy for Prostate Cancer Number: NCT04842890 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): The New York Proton Center Sponsor Trial Information Trial Location(s) and Contact(s):
Phase II Study of Pencil Beam Scanning Proton Stereotactic Body Radiation Therapy for Prostate Cancer Number: NCT04842890 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): The New York Proton Center Sponsor Trial Information Trial Location(s) and Contact(s):	Phase II Study of Pencil Beam Scanning Proton Stereotactic Body Radiation Therapy for Prostate Cancer Number: NCT04842890 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): The New York Proton Center Sponsor Trial Information Trial Location(s) and Contact(s):
Phase II Study of Pencil Beam Scanning Proton Stereotactic Body Radiation Therapy for Prostate Cancer Number: NCT04842890 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): The New York Proton Center Sponsor Trial Information Trial Location(s) and Contact(s):	Phase II Study of Pencil Beam Scanning Proton Stereotactic Body Radiation Therapy for Prostate Cancer Number: NCT04842890 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): The New York Proton Center Sponsor Trial Information Trial Location(s) and Contact(s):
Phase II Study of Pencil Beam Scanning Proton Stereotactic Body Radiation Therapy for Prostate Cancer Number: NCT04842890 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): The New York Proton Center Sponsor Trial Information Trial Location(s) and Contact(s):	Phase II Study of Pencil Beam Scanning Proton Stereotactic Body Radiation Therapy for Prostate Cancer Number: NCT04842890 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): The New York Proton Center Sponsor Trial Information Trial Location(s) and Contact(s):
Evaluation of Transperineal Biopsy Under Local Anesthesia Number: NCT04843566 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent Number: NCT04844749 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Veru Inc. Sponsor Trial Information Trial Location(s) and Contact(s):
Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC Number: NCT04846478 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Dana-Farber Cancer Institute\|Epizyme, Inc.\|Pfizer Sponsor Trial Information Trial Location(s) and Contact(s):	Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer Number: NCT04848337 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Ulka Vaishampayan\|Merck Sharp & Dohme Corp.\|University of Michigan\|Hoosier Cancer Research Network Sponsor Trial Information Trial Location(s) and Contact(s):
99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer Number: NCT04857502 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): Jonsson Comprehensive Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s):	99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer Number: NCT04857502 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): Jonsson Comprehensive Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s):
99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer Number: NCT04857502 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): Jonsson Comprehensive Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s):	Digital PET/CT Using [Ga-68]PSMA for Characterization of Prostate Lesions Number: NCT04867603 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Norbert Avril, M.D.\|Case Comprehensive Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s):
Digital PET/CT Using [Ga-68]PSMA for Characterization of Prostate Lesions Number: NCT04867603 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Norbert Avril, M.D.\|Case Comprehensive Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s):	64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE) Number: NCT04868604 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Clarity Pharmaceuticals Ltd Sponsor Trial Information Trial Location(s) and Contact(s):
Diet and Physical Activity Intervention for the Prevention of ADT-Induced Metabolic Changes in Patients With Prostate Cancer, TRIPLE-A PILOT Study Number: NCT04870515 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	Diet and Physical Activity Intervention for the Prevention of ADT-Induced Metabolic Changes in Patients With Prostate Cancer, TRIPLE-A PILOT Study Number: NCT04870515 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization Number: NCT04879940 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): H. Lee Moffitt Cancer Center and Research Institute Sponsor Trial Information Trial Location(s) and Contact(s):	Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization Number: NCT04879940 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): H. Lee Moffitt Cancer Center and Research Institute Sponsor Trial Information Trial Location(s) and Contact(s):
Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization Number: NCT04879940 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): H. Lee Moffitt Cancer Center and Research Institute Sponsor Trial Information Trial Location(s) and Contact(s):	Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization Number: NCT04879940 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): H. Lee Moffitt Cancer Center and Research Institute Sponsor Trial Information Trial Location(s) and Contact(s):
Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization Number: NCT04879940 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): H. Lee Moffitt Cancer Center and Research Institute Sponsor Trial Information Trial Location(s) and Contact(s):	Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization Number: NCT04879940 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): H. Lee Moffitt Cancer Center and Research Institute Sponsor Trial Information Trial Location(s) and Contact(s):
Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization Number: NCT04879940 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): H. Lee Moffitt Cancer Center and Research Institute Sponsor Trial Information Trial Location(s) and Contact(s):	225Ac-J591 Plus 177Lu-PSMA-I&T for mCRPC Number: NCT04886986 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Weill Medical College of Cornell University\|POINT Biopharma Sponsor Trial Information Trial Location(s) and Contact(s):
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation Number: NCT04890613 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Senhwa Biosciences, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):	A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer Number: NCT04898634 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Janssen Research & Development, LLC Sponsor Trial Information Trial Location(s) and Contact(s):
A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer Number: NCT04898634 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Janssen Research & Development, LLC Sponsor Trial Information Trial Location(s) and Contact(s):	A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer Number: NCT04898634 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Janssen Research & Development, LLC Sponsor Trial Information Trial Location(s) and Contact(s):
Effectiveness of the SpaceOAR Vue System in Subjects With Prostate Cancer Being Treated With Stereotactic Body Radiotherapy Number: NCT04905069 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics Number: NCT04905082 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy Number: NCT04915508 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Jonsson Comprehensive Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s):	Study of XB002 in Subjects With Solid Tumors (JEWEL-101) Number: NCT04925284 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Exelixis Sponsor Trial Information Trial Location(s) and Contact(s):
Study of XB002 in Subjects With Solid Tumors (JEWEL-101) Number: NCT04925284 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Exelixis Sponsor Trial Information Trial Location(s) and Contact(s):	Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer Number: NCT04926181 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Rahul Aggarwal\|Janssen Scientific Affairs, LLC\|University of California, San Francisco Sponsor Trial Information Trial Location(s) and Contact(s):
11C-YJH08 PET Imaging for the Detection of Glucocorticoid Receptor Expression in Patients With Metastatic Prostate Cancer Number: NCT04927663 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Michael Evans\|U.S. Army Medical Research Acquisition Activity\|National Institute of Mental Health (NIMH)\|University of California, San Francisco Sponsor Trial Information Trial Location(s) and Contact(s)	11C-YJH08 PET Imaging for the Detection of Glucocorticoid Receptor Expression in Patients With Metastatic Prostate Cancer Number: NCT04927663 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Michael Evans\|U.S. Army Medical Research Acquisition Activity\|National Institute of Mental Health (NIMH)\|University of California, San Francisco Sponsor Trial Information Trial Location(s) and Contact(s)
11C-YJH08 PET Imaging for the Detection of Glucocorticoid Receptor Expression in Patients With Metastatic Prostate Cancer Number: NCT04927663 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Michael Evans\|U.S. Army Medical Research Acquisition Activity\|National Institute of Mental Health (NIMH)\|University of California, San Francisco Sponsor Trial Information Trial Location(s) and Contact(s)	Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors Number: NCT04931823 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Conjupro Biotherapeutics, Inc.\|CSPC ZhongQi Pharmaceutical Technology Co., Ltd. Sponsor Trial Information Trial Location(s) and Contact(s):
Bicalutamide Implants (Biolen) With Radiation Therapy in Patients With Localized Prostate Cancer Number: NCT04943536 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Alessa Therapeutics Inc.\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate Adenocarcinoma Number: NCT04945642 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate Adenocarcinoma Number: NCT04945642 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	Maximizing Responses to Anti-PD1 Immunotherapy With PSMA-targeted Alpha Therapy in mCRPC Number: NCT04946370 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Weill Medical College of Cornell University\|United States Department of Defense\|Merck Sharp & Dohme LLC Sponsor Trial Information Trial Location(s) and Contact(s):
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer Number: NCT04947254 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): M.D. Anderson Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s):	Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma Number: NCT04951492 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors Number: NCT04957290 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Noxopharm Limited Sponsor Trial Information Trial Location(s) and Contact(s):	Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue Number: NCT04972097 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Pharmacokinetics of IA and IV Ga68-PSMA-11 Infusion Number: NCT04976257 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): Ryan Kohlbrenner, MD\|Radiological Society of North America\|University of California, San Francisco Sponsor Trial Information Trial Location(s) and Contact(s):	Pharmacokinetics of IA and IV Ga68-PSMA-11 Infusion Number: NCT04976257 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): Ryan Kohlbrenner, MD\|Radiological Society of North America\|University of California, San Francisco Sponsor Trial Information Trial Location(s) and Contact(s):
An Investigational Scan (rh PSMA 7.3 PET/MRI) for the Detection of Recurrent Disease and Aid in Radiotherapy Planning in Biochemically Recurrent Prostate Cancer Number: NCT04978675 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): M.D. Anderson Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s):	Predicting Location and Extent of Prostate Cancer Using Micro-Ultrasound Imaging Number: NCT04981223 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Robot-Assisted Radical Prostatectomy With or Without Vesicopexy in Patients With Prostate Cancer Number: NCT04981834 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	Randomized Trial of Five or Two MRI-Guided Adaptive Radiotherapy Treatments for Prostate Cancer Number: NCT04984343 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Weill Medical College of Cornell University\|Viewray Inc.\|Progenics Pharmaceuticals, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):
Randomized Trial of Five or Two MRI-Guided Adaptive Radiotherapy Treatments for Prostate Cancer Number: NCT04984343 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Weill Medical College of Cornell University\|Viewray Inc.\|Progenics Pharmaceuticals, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):	Neoadjuvant Dietary Intervention in Intermediate Risk Prostate Cancer Number: NCT04985565 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer Number: NCT04986423 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Zenith Epigenetics\|Astellas Pharma Inc\|Newsoara Biopharma Co., Ltd. Sponsor Trial Information Trial Location(s) and Contact(s):	Androgen Deprivation, With or Without pTVG-AR, and With or Without Nivolumab, in Patients With Newly Diagnosed, High-Risk Prostate Cancer Number: NCT04989946 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): University of Wisconsin, Madison\|Madison Vaccines, Inc\|United States Department of Defense Sponsor Trial Information Trial Location(s) and Contact(s):
PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness Number: NCT04995198 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Prostate Cancer Clinical Trials Consortium\|Memorial Sloan Kettering Cancer Center\|Fred Hutchinson Cancer Center\|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|Advancing Cancer Treatment, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):	PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness Number: NCT04995198 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Prostate Cancer Clinical Trials Consortium\|Memorial Sloan Kettering Cancer Center\|Fred Hutchinson Cancer Center\|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|Advancing Cancer Treatment, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):
Insulin Resistance and Androgen Deprivation Therapy Number: NCT04995978 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): St. Louis University Sponsor Trial Information Trial Location(s) and Contact(s):	Insulin Resistance and Androgen Deprivation Therapy Number: NCT04995978 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): St. Louis University Sponsor Trial Information Trial Location(s) and Contact(s):
A Study of MRI-guided High-dose Radiation Therapy in Prostate Cancer Number: NCT04997018 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Memorial Sloan Kettering Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s):	XmAb®20717 Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer Number: NCT05005728 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Xencor, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):
The Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in the Adjuvant Setting. Number: NCT05010200 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Ashutosh Kumar Tewari\|Icahn School of Medicine at Mount Sinai Sponsor Trial Information Trial Location(s) and Contact(s):	The Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in the Adjuvant Setting. Number: NCT05010200 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Ashutosh Kumar Tewari\|Icahn School of Medicine at Mount Sinai Sponsor Trial Information Trial Location(s) and Contact(s):
Study of Focal Ablation of the Prostate With NanoTherm® Therapy System for Intermediate-Risk Prostate Cancer Number: NCT05010759 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer Number: NCT05011188 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Rahul Aggarwal\|Fortis Therapeutics, Inc.\|University of California, San Francisco Sponsor Trial Information Trial Location(s) and Contact(s):
High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers Number: NCT05011383 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): VA Office of Research and Development Sponsor Trial Information Trial Location(s) and Contact(s):	A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants Number: NCT05022849 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Janssen Research & Development, LLC Sponsor Trial Information Trial Location(s) and Contact(s):
A Comparison of TULSA Procedure vs. Radical Prostatectomy in Participants With Localized Prostate Cancer Number: NCT05027477 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	A Study of XmAb20717 in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies Number: NCT05032040 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Xencor, Inc.\|ICON plc Sponsor Trial Information Trial Location(s) and Contact(s):
COAST Therapy in Advanced Solid Tumors and Prostate Cancer Number: NCT05036226 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Medical University of South Carolina Sponsor Trial Information Trial Location(s) and Contact(s):	Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer Number: NCT05037500 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Roswell Park Cancer Institute\|National Comprehensive Cancer Network Sponsor Trial Information Trial Location(s) and Contact(s):
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT]) Number: NCT05038332 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Michigan Rogel Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s):	Diagnostic Performance Of Non-Endorectal Coil Multiparametric Magnetic Resonance Imaging Of Prostate With Flexible AIR Coil (DoNEMAC Study) Number: NCT05043012 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Differences in Immunological Effects of Vitamin D Replacement Among African American Prostate Cancer Patients With Localized Versus Metastatic Disease Number: NCT05045066 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): Mayo Clinic\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	Differences in Immunological Effects of Vitamin D Replacement Among African American Prostate Cancer Patients With Localized Versus Metastatic Disease Number: NCT05045066 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): Mayo Clinic\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
Differences in Immunological Effects of Vitamin D Replacement Among African American Prostate Cancer Patients With Localized Versus Metastatic Disease Number: NCT05045066 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): Mayo Clinic\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	KZR-261 in Subjects With Advanced Solid Malignancies Number: NCT05047536 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Kezar Life Sciences, Inc. Sponsor Trial Information Trial Location(s) and Contact(s):
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score Number: NCT05050084 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): NRG Oncology\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score Number: NCT05050084 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): NRG Oncology\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer Number: NCT05053152 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): NRG Oncology\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring Number: NCT05054296 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): M.D. Anderson Cancer Center\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
Novel Synthetic T2W MR Imaging and Spin Parameter Mapping Techniques for Screening Prostate Cancer Number: NCT05055843 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	Novel Synthetic T2W MR Imaging and Spin Parameter Mapping Techniques for Screening Prostate Cancer Number: NCT05055843 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study. Number: NCT05059236 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Bayer Sponsor Trial Information Trial Location(s) and Contact(s):	Clinical Trial to Evaluate ARV-766 in Patients With Metastatic Castration-Resistant Prostate Cancer Number: NCT05067140 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Arvinas Androgen Receptor, Inc.\|Arvinas Inc. Sponsor Trial Information Trial Location(s) and Contact(s):
Massage for Prostate Cancer-Related Fatigue, mPROSTATE Study Number: NCT05067777 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Utah\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	EPI-7386 in Combination With Enzalutamide Compared With Enzalutamide Alone in Subjects With mCRPC Number: NCT05075577 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): ESSA Pharmaceuticals Sponsor Trial Information Trial Location(s) and Contact(s):
Study of ADXS-504 Immunotherapy for Recurrent Prostate Cancer Number: NCT05077098 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Mark Stein\|Columbia University Sponsor Trial Information Trial Location(s) and Contact(s):	Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer Number: NCT05081193 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|Clarus Therapeutics Sponsor Trial Information Trial Location(s) and Contact(s):
Pioglitazone and Insulin Resistance in ADT Number: NCT05098327 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): State University of New York at Buffalo Sponsor Trial Information Trial Location(s) and Contact(s):	Pioglitazone and Insulin Resistance in ADT Number: NCT05098327 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): State University of New York at Buffalo Sponsor Trial Information Trial Location(s) and Contact(s):
A Study of Shorter Course Hormone Therapy and Radiation for High-risk Prostate Cancer Number: NCT05100472 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Memorial Sloan Kettering Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s):	Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer Number: NCT05113537 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Vadim S Koshkin\|Prostate Cancer Foundation\|Eli Lilly and Company\|University of California, San Francisco Sponsor Trial Information Trial Location(s) and Contact(s):
REGN4336 (a PSMAXCD3 Bispecific Antibody) Administered Alone or in Combination With Cemiplimab in Adult Male Patients With Metastatic Castration-Resistant Prostate Cancer Number: NCT05125016 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Regeneron Pharmaceuticals Sponsor Trial Information Trial Location(s) and Contact(s):	A Study of Stereotactic Body Radiation Therapy and Radium (Ra-223) Dichloride in Prostate Cancer That Has Spread to the Bones Number: NCT05133440 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Memorial Sloan Kettering Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s):
18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy Number: NCT05155046 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s):	Adjuvant High-intensity Interval Training During Chemotherapy in Metastatic Prostate Cancer Patients Number: NCT05156372 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Adjuvant High-intensity Interval Training During Chemotherapy in Metastatic Prostate Cancer Patients Number: NCT05156372 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	Study of Docetaxel Combined With Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer Number: NCT05156905 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
A Study of PRT2527 in Patients With Advanced Solid Tumors Number: NCT05159518 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Prelude Therapeutics Sponsor Trial Information Trial Location(s) and Contact(s):	A Study of PRT2527 in Patients With Advanced Solid Tumors Number: NCT05159518 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Prelude Therapeutics Sponsor Trial Information Trial Location(s) and Contact(s):
Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive Biopsy Number: NCT05160597 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): Jonsson Comprehensive Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s):	Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive Biopsy Number: NCT05160597 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): Jonsson Comprehensive Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s):
Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive Biopsy Number: NCT05160597 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): Jonsson Comprehensive Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s):	Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial Number: NCT05168618 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Utah\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):
A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer Number: NCT05169684 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Bristol-Myers Squibb Sponsor Trial Information Trial Location(s) and Contact(s):	A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer Number: NCT05169970 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Memorial Sloan Kettering Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s):
A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer Number: NCT05169970 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Memorial Sloan Kettering Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s):	Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors Number: NCT05176483 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Exelixis Sponsor Trial Information Trial Location(s) and Contact(s):
Trial of ARV-110 and Abiraterone in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) Number: NCT05177042 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Arvinas Androgen Receptor, Inc.\|Arvinas Inc. Sponsor Trial Information Trial Location(s) and Contact(s):	First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer Number: NCT05189457 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): H. Lee Moffitt Cancer Center and Research Institute\|BeiGene Sponsor Trial Information Trial Location(s) and Contact(s):
Lu-177-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer Number: NCT05204927 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Curium US LLC Sponsor Trial Information Trial Location(s) and Contact(s):	Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors Number: NCT05215574 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): NGM Biopharmaceuticals, Inc\|Merck Sharp & Dohme LLC Sponsor Trial Information Trial Location(s) and Contact(s):
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors Number: NCT05215574 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): NGM Biopharmaceuticals, Inc\|Merck Sharp & Dohme LLC Sponsor Trial Information Trial Location(s) and Contact(s):	Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors Number: NCT05215574 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): NGM Biopharmaceuticals, Inc\|Merck Sharp & Dohme LLC Sponsor Trial Information Trial Location(s) and Contact(s):
Targeted Alpha Therapy With 225Actinium-PSMA-I&T of Castration-resISTant Prostate Cancer (TATCIST). Number: NCT05219500 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Excel Diagnostics and Nuclear Oncology Center Sponsor Trial Information Trial Location(s) and Contact(s):	Targeted Alpha Therapy With 225Actinium-PSMA-I&T of Castration-resISTant Prostate Cancer (TATCIST). Number: NCT05219500 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Excel Diagnostics and Nuclear Oncology Center Sponsor Trial Information Trial Location(s) and Contact(s):
Rectal Spacer Hydrogel Before Radiation Therapy in Reducing Radiation Dose to the Rectum in Patients With Prostate Cancer Number: NCT05224869 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Icahn School of Medicine at Mount Sinai Sponsor Trial Information Trial Location(s) and Contact(s):	A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer Number: NCT05241613 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Accutar Biotechnology Inc Sponsor Trial Information Trial Location(s) and Contact(s):
PET Imaging Study of 89Zr-DFO-YS5 Number: NCT05245006 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Robert Flavell, MD, PhD\|United States Department of Defense\|Fortis Therapeutics, Inc.\|University of California, San Francisco Sponsor Trial Information Trial Location(s) and Contact(s):	64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer (COBRA) Number: NCT05249127 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Clarity Pharmaceuticals Ltd Sponsor Trial Information Trial Location(s) and Contact(s):
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors Number: NCT05252390 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Nuvation Bio Inc. Sponsor Trial Information Trial Location(s) and Contact(s):	A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors Number: NCT05268666 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Jubilant Therapeutics Inc. Sponsor Trial Information Trial Location(s) and Contact(s):
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) Number: NCT05288166 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Eli Lilly and Company Sponsor Trial Information Trial Location(s) and Contact(s):	A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) Number: NCT05288166 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Eli Lilly and Company Sponsor Trial Information Trial Location(s) and Contact(s):
A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors Number: NCT05293496 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): MacroGenics Sponsor Trial Information Trial Location(s) and Contact(s):	Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors Number: NCT05311618 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): NGM Biopharmaceuticals, Inc\|Merck Sharp & Dohme LLC Sponsor Trial Information Trial Location(s) and Contact(s):
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors Number: NCT05311618 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): NGM Biopharmaceuticals, Inc\|Merck Sharp & Dohme LLC Sponsor Trial Information Trial Location(s) and Contact(s):	Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors Number: NCT05313191 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
RElugolix VErsus LeUprolide Cardiac Trial Number: NCT05320406 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 4 Sponsor(s): Emory University\|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s):	Leveraging Technology to Achieve Equity for Men With Prostate Cancer on Androgen Deprivation Therapy Number: NCT05324098 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
An Imaging Agent (Perflutren Lipid Microspheres) With Ultrasound for Imaging of Prostate Cancer Number: NCT05336786 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Thomas Jefferson University Sponsor Trial Information Trial Location(s) and Contact(s):	Feasibility Study of Radiation Therapy and IRreversible Electroporation for Intermediate Risk Prostate Cancer (RTIRE) Number: NCT05345444 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC) Number: NCT05348577 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): AstraZeneca Sponsor Trial Information Trial Location(s) and Contact(s):	T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine M9241 in Localized High- and Intermediate-Risk Prostate Cancer Treated With Androgen Deprivation Therapy Number: NCT05361798 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine M9241 in Localized High- and Intermediate-Risk Prostate Cancer Treated With Androgen Deprivation Therapy Number: NCT05361798 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	Patient-Reported Erectile Recovery and Quality of Life Outcomes With Lyopreserved Placental Tissue Applied Directly Over Neurovascular Bundle During Nerve Sparing Radical Prostatectomy Versus Standard of Care Number: NCT05366842 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Johns Hopkins University Sponsor Trial Information Trial Location(s) and Contact(s):
Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer Number: NCT05369000 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Lava Therapeutics Sponsor Trial Information Trial Location(s) and Contact(s):	AGN-CognI.Q Acute Dose Safety and Pharmacokinetics Dose-Response in Prostate Cancer Patients Number: NCT05375539 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
PSMA-PET to Guide Prostatectomy Number: NCT05381103 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2\|Phase 3 Sponsor(s): Five Eleven Pharma, Inc.\|Indiana University Sponsor Trial Information Trial Location(s) and Contact(s):	Utility of Biparametric MRI (Magnetic Resonance Imaging) as a Screening Tool for Prostate Cancer in a High-Risk Cohort Number: NCT05384535 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Patient Decision-making About Precision Oncology in Veterans With Advanced Prostate Cancer Number: NCT05396872 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer (SABRE) Number: NCT05407311 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Study of ORIC-944 in Patients With Metastatic Prostate Cancer Number: NCT05413421 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): ORIC Pharmaceuticals Sponsor Trial Information Trial Location(s) and Contact(s):	Study of ORIC-944 in Patients With Metastatic Prostate Cancer Number: NCT05413421 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): ORIC Pharmaceuticals Sponsor Trial Information Trial Location(s) and Contact(s):
Study of ORIC-944 in Patients With Metastatic Prostate Cancer Number: NCT05413421 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): ORIC Pharmaceuticals Sponsor Trial Information Trial Location(s) and Contact(s):	Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection Number: NCT05413850 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Blue Earth Therapeutics Ltd\|PSI CRO Sponsor Trial Information Trial Location(s) and Contact(s):
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas Number: NCT05415098 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies Number: NCT05417594 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): AstraZeneca Sponsor Trial Information Trial Location(s) and Contact(s):
MRI And GPS Informing Choices for Prostate Cancer Treatment (MAGIC) Number: NCT05424783 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	MRI And GPS Informing Choices for Prostate Cancer Treatment (MAGIC) Number: NCT05424783 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
MRI-guided Transurethral Urethral Ultrasound Ablation for the Treatment of Intermediate Grade Prostate Cancer Number: NCT05438563 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	A Study of JNJ-80038114 in Participants With Advanced Stage Prostate Cancer Number: NCT05441501 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
An Evidence-Based Focal Cryotherapy Protocol for Focal Ablation of Intermediate Risk Prostate Cancer Number: NCT05454488 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): M.D. Anderson Cancer Center\|Philanthropic Sources Sponsor Trial Information Trial Location(s) and Contact(s):	Imaging and Genomic Biomarkers to Predict Response in Prostate Cancer Number: NCT05477823 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer Number: NCT05479578 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Rashmi Verma, MD\|National Cancer Institute (NCI)\|University of California, Davis Sponsor Trial Information Trial Location(s) and Contact(s):	Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours Number: NCT05489211 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) Number: NCT05489991 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1\|Phase 2 Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study Number: NCT05496959 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01) Number: NCT05519449 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	MGC018 Versus Androgen Receptor Axis-targeted Therapy in Participants With Metastatic Castration Resistant Prostate Cancer Number: NCT05551117 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2\|Phase 3 Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors Number: NCT05585034 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):	Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors Number: NCT05585034 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):
Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers Number: NCT05588609 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s):

Total: 623 Clinical Trials

PHEN,Inc. © 2024 All rights reserved